Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Large-Scale Lentiviral Vector Manufacturing for Cell Therapies

PROVEN INTELLIGENCE IN LENTIVIRAL VECTOR CMC

Large-Scale Lentiviral Vector Production for UK-Based Cell Therapy Innovators

CELL & GENE | RNA | BIOLOGICS

A scientist in a modern lab analyzes colorful DNA sequencing data on a tablet.

Executive Summary

Large-scale lentiviral (LV) vector production for UK-based cell therapy programs requires specific technical considerations for successful MHRA submissions. The process development, analytical characterization, and GxP-compliant manufacturing are foundational for supporting autologous and allogeneic cell-based modalities like CAR-T and TCR-T therapies. The focus is on generating high-titer, functionally potent vectors suitable for Investigational Medicinal Product Dossier (IMPD) submissions and subsequent clinical application.

Frequently Asked Questions

How does Franklin Biolabs ensure LV vector quality for ATMP submissions to the MHRA?

We employ a phase-appropriate approach to vector analytics and process development. This includes rigorous testing for vector identity, purity, potency, and safety. Our processes are designed to meet the stringent requirements for Advanced Therapy Medicinal Products (ATMPs), ensuring that the vector lots supplied for ex vivo cell transduction are well-characterized and compliant with UK and EU regulatory expectations.

What is the typical timeline for producing a clinical-grade lentiviral vector for a CAR-T program?

While each program is unique, our platform processes and experienced scientific team enable an 18-24 month timeline to get candidates to IND or IMPD submission. This track record is based on the deep operational history of our core scientific leadership, whose 100% successful IND rate since 2019 was established prior to the formal launch of Franklin Biolabs in 2024.

Can you support both early-phase research and large-scale clinical production of lentiviral vectors?

Yes. We provide a continuous path from small-scale research vectors for initial proof-of-concept work to large-scale, GxP-compliant production runs sufficient for pivotal clinical trials. This continuity is a core part of our model, ensuring process knowledge is retained as your program advances.

Large-Scale Lentiviral Vector Production for Cell Therapy Programs

The manufacturing of lentiviral vectors for ex vivo cell modification presents distinct challenges. The primary goal is to produce high-titer, replication-incompetent vectors that can efficiently transduce target cells, such as T-cells or hematopoietic stem cells, without compromising their viability or function. This requires a robust and scalable upstream and downstream process.

Our approach focuses on several key areas:

  • Plasmid Quality Control: The process begins with stringent qualification of the transfer, packaging, and envelope plasmids to ensure consistency and safety.

  • Scalable Cell Culture: We utilize suspension-based culture systems to enable scalable production, moving from small-scale flasks to large-volume bioreactors while maintaining process control.

  • Downstream Purification: The purification strategy is designed to remove process-related impurities, such as host cell proteins and DNA, while maximizing the recovery of functionally active vector particles.

A close-up of a multi-channel pipette dispensing liquid into a microplate in a laboratory setting, with a blue color overlay.

Phase-Appropriate Analytics and Regulatory Alignment

A tailored analytical strategy is fundamental for any cell therapy program targeting MHRA submission. We develop and qualify a suite of assays to characterize each LV vector lot, providing the data package necessary for an IMPD. This includes assays for physical titer (genomic copies), functional titer (transducing units), and purity.

The history of advanced therapies has demonstrated that vector design and administration are directly linked to clinical outcomes (PMID: 19211285). Even in preclinical models, the choice of vector can have profound and differential effects on biological systems (PMID: 27937051). This knowledge informs our rigorous approach to vector characterization, ensuring that every batch meets predefined specifications before being used to manufacture a cell-based therapeutic.

A biotech sponsor commented on the team’s expertise: “Wonderful services. Excellent team to work with. Vast knowledge in all aspects of vector production and analytics.” This institutional knowledge is applied across all vector platforms.

Our extensive facilities, spanning over 100,000 square feet of specialized laboratory and housing space, provide the infrastructure to execute these complex manufacturing and analytical programs. This integrated environment supports the entire workflow, from vector production to the bioanalysis of samples from downstream efficacy studies.

For a broader overview of our vector manufacturing platforms, including AAV systems, please see our parent hub page on Large-Scale AAV Manufacturing and Process Development.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities